Abstract:Twenty-eight patients with a median age of 38 (15~54) years received allogeneic peripheral blood stem cell transplantation (allo-HSCT). Diagnoses included AML (n=7), ALL (n=2), CML (n=13), MM (n=4), MDS (n=1) and advanced ovarian cancer (n=1). Thirteen patients of them had progressive diseases. Myeloablative conditioning was given to 12 patients and non-myeloablative conditioning to 16 patients. FACS sorted granulocytes, T lymphocytes, B lymphocytes and NK cells from peripheral blood of all patients were analyzed for PCR amplification of short tandem repeats. The purity of sorted cells was above 96%. On day 7 posttransplant, the chimerism of NK cells was the highest in 88.5% patients, indicating that NK cells were the earliest engrafting cells. The subpopulations of granulocytes, B lymphocytes and NK cells reached complete chimerism (CC) on a median of day 14 posttransplant, while T lymphocytes were the latest subpopulation to reach CC in both myeloablative and non-myeloablative transplant on a median of day 21 and day 28 posttransplant, respectively. Seven patients with myeloid malignancy had molecular omen of graft rejection or disease relapse. Three patients of them had chimerism of donor T cells shifting from CC to MC only, while other subpopulation of cells remained CC. T cell chimerism in 2 patients of them remained lowest level among all subpopulation of cells. Recipient T cells had decreasing MC in 5 cases after discontinuance of immunosuppressant and donor lymphocyte infusion, 3 of them achieved CC again. Eight cases developed acute GVHD in 19 stable CC patients. Seven of them had GVHD after CC was achieved by all cell subsets. None of the patients in unstable CC group developed GVHD before they had graft rejection or relapse. The rate of acute GVHD of CC group was higher than MC group(χ2=4.25, P<0.05). We conclude that donor T lymphocytes are the earliest subpopulation of cells to subside during the course of graft rejection and disease relapse in myeloid malignancy. Patients responding to adjustment of immunosuppressants and/or DLI could achieve CC of T lymphocyte fraction again. CC of T lymphocyte could be a marker of stable engraftment of donor cells. Progressive MC of T cell is the omen of graft rejection and disease relapse. Immunosuppressant dosage should be adjusted according to T lymphocyte chimerism for different patients. GVHD prevention should be preferred in patients who reach CC in T cell fraction in one month after transplant. Therefore we suggest the patients might be given higher dose and longer period of immunosuppressants in 3 months posttransplant. In order to promote the engraftment of donor cell and avoid disease recurrence, the immunosuppressants might be tapered in the patients who do not reach CC in T cell fraction in one month after transplant and the patients with progressive MC in T cell.

Combined Host-Conditioning with CTLA4-Ig, Tacrolimus, Anti-Lymphocyte Serum, and Low-Dose Radiation Leads to Stable Mixed Hematopoietic Chimerism

Simultaneous Blockade of Costimulatory Signals CD28-CD80 and CD40-CD154 Combined with Monoclonal Antibody Against CD25 Induced a Stable Chimerism and Tolerance Without Graft-Versus-host Disease in Rat.

Low dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen

Effects of chimerism on the mice heart transplanted survival with the bone marrow infusion.

Adjustment Of Immonosuppressants Based On T Lymphocyte Chimerism Following Allogeneic Hematopoietic Stem Cell Transplantation.

Early allogeneic immune modulation after establishment of donor hematopoietic cell-induced mixed chimerism in a nonhuman primate kidney transplant model

Effects of short-course immunosuppression on chimerism and tolerance indhuced by bone marrow transplantation without cytoreductive conditioning

Effects of sensitized donor lymphocyte infusion on the chimerism and graft-versus-host disease after nonmyeloablative allogeneic stem cell transplantation]

Establishment of a Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Model in Mice and Its Related Study

Selective elimination of alloreactive donor lymphocytes by using TBI and cyclophosphamide]

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation

Transplantation of Donor-Recipient Chimeric Cells Restores Peripheral Blood Cell Populations and Increases Survival after Total Body Irradiation-Induced Injury in a Rat Experimental Model

Transplantation after CD45-ADC corrects Rag1 immunodeficiency in congenic and haploidentical settings

An experimental study of immune depression to donor origin cells induced by the mixed chimera after sublethal whole body irradiation

Efficacy of splenocytes in inducing stable long-term chimerism in murine mixed haploidentical MHC matched bone marrow transplant model

Donor-Recipient Chimeric Cell Transplantation as the Bridging Therapy for Mitigating Total Body Irradiation-Induced Injury

Induction of Allogeneic Mixed Chimerism by Immature Dendritic Cells and Bone Marrow Transplantation Leads to Prolonged Tolerance to Major Histocompatibility Complex Disparate Allografts

Combined Treatment of Allograft Recipients with CTLA-4 Ig and Anti-Icam-1 Mab Plus Transfusion of Donor-Specific DC Progenitors

Mixed Chimerism Induces Donor-Specific T-cell Tolerance Across a Highly Disparate Xenogeneic Barrier.